- Home
- PETZ vs VYNE Comparison
PETZ vs VYNE Comparison
Compare PETZ & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | VYNE |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.7M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PETZ | VYNE |
|---|---|---|
| Price | $1.04 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.5K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,046,006.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | $6.39 | ★ N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.65 | $0.28 |
| 52 Week High | $1.68 | $4.30 |
Technical Indicators
Market Signals| Indicator | PETZ | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 53.02 |
| Support Level | $1.01 | $0.35 |
| Resistance Level | $1.08 | $0.40 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 46.15 | 59.31 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.